A Nationwide Multicenter Study on 1-Year Outcomes of Posterior Chamber Phakic Intraocular Lens Implantation for Low Myopia

Kazutaka Kamiya; Kimiya Shimizu; Akihito Igarashi; Yoshihiro Kitazawa; Takashi Kojima; Tomoaki Nakamura; Kazuo Ichikawa; Sachiko Fukuoka; Kahoko Fujimoto; Japan ICL Study Group

doi:10.3389/fmed.2022.762153

A Nationwide Multicenter Study on 1-Year Outcomes of Posterior Chamber Phakic Intraocular Lens Implantation for Low Myopia

Front Med (Lausanne). 2022 May 4:9:762153. doi: 10.3389/fmed.2022.762153. eCollection 2022.

Authors

Kazutaka Kamiya¹, Kimiya Shimizu², Akihito Igarashi², Yoshihiro Kitazawa³, Takashi Kojima⁴, Tomoaki Nakamura⁵, Kazuo Ichikawa⁶, Sachiko Fukuoka⁷, Kahoko Fujimoto⁸; Japan ICL Study Group

Affiliations

¹ Visual Physiology, School of Allied Health Sciences, Kitasato University, Tokyo, Japan.
² Department of Ophthalmology, Sanno Hospital, Tokyo, Japan.
³ Department of Ophthalmology, Sapia Tower Eye Clinic Tokyo, Tokyo, Japan.
⁴ Department of Ophthalmology, Keio University, Tokyo, Japan.
⁵ Department of Ophthalmology, Nagoya Eye Clinic, Aichi, Japan.
⁶ Department of Ophthalmology, Chukyo Eye Clinic, Aichi, Japan.
⁷ Department of Ophthalmology, Tane Memorial Eye Hospital, Osaka, Japan.
⁸ Department of Ophthalmology, Fujimoto Eye Clinic, Osaka, Japan.

Abstract

Purpose: To assess the nationwide multicenter outcomes of posterior chamber phakic intraocular lens implantation with a central hole (EVO-ICL, STAAR Surgical) for patients with low myopia.

Methods: This multicenter study comprised 172 eyes of 111 consecutive patients undergoing hole ICL implantation to correct low myopia and myopic astigmatism [manifest spherical equivalent (MSE);-3 diopters (D) or less] at seven nationwide major surgical facilities. We retrospectively determined safety, efficacy, predictability, stability, and adverse events at 1 week, 1, 3, 6, and 12 months postoperatively, and at the final visit.

Results: The mean follow-up period was 1.4 ± 1.0 years. Uncorrected and corrected visual acuities at 1 year postoperatively were -0.17 ± 0.12 and -0.24 ± 0.07 logarithm of the minimal angle of resolution (logMAR), respectively. At 1 year postoperatively, 91% and 100% of eyes were within 0.5 and 1.0 D of the target correction, respectively. No significant manifest refraction changes of -0.07 ± 0.26 D occurred from 1 week to 1 year. No vision-threatening complications occurred at any time in this series.

Conclusions: According to our experience, the EVO-ICL performed well without significant complications throughout the 1-year observation period, even for the correction of low myopia. It is suggested that current ICL implantation is one of the viable surgical options for correcting low myopia.

Keywords: EVO-ICL; efficacy; endothelial cell density; low myopia; phakic IOL; predictability; safety; stability.